Since glutamatergic signaling is of key significance in the pathobiology of neuropsychiatric diseases, including schizophrenia (27, 28, 29, 30, 31), we selected a previously published clonal hiPSC line harboring an inducible Neurogenin 2 (NGN2) driven by a doxycycline-inducible promoter for glutamatergic differentiation (32). This evidence concerns the gene NEUROG2 and schizophrenia.